Alentis Therapeutics AG

Clinical-stage biotech company. It is advancing monoclonal antibodies and antibody-drug conjugates that bind exposed CLDN1 in tumors and fibrotic tissue. By targeting Claudin-1 it addresses Claudin-1 positive solid tumors and organ fibrosis. Source

Keywords: Claudin-1 CLDN1 monoclonal antibodies antibody-drug conjugates solid tumors organ fibrosis Show all 6 keywords